Background

Estrogen receptor-positive (ER+) breast cancer is the most common subtype, accounting for approximately 70% of all breast cancer patients. For postmenopausal patients, aromatase inhibitors (AIs), which block estrogen production, are widely used as standard first-line endocrine therapy. This is the principle of depleting female hormones that promote tumor growth, thereby causing cancer cells to die.

The problem is that treatment responses vary drastically from patient to patient. While some patients experience long-term tumor suppression, a significant number do not respond to the drug or acquire resistance shortly after starting treatment, leading to disease progression. Previous research has primarily focused on identifying specific mutations in cancer cell DNA. However, genomic sequencing alone was insufficient to fully explain the dynamic interactions between cellular state changes and the immune environment that occur during drug administration. This underscores the urgent need for precise tracking studies capable of capturing subtle molecular changes within tumors before and after treatment.

Key Findings

An international research team conducted longitudinal single-cell analysis to track tissue samples from ER-positive breast cancer patients receiving AI therapy over time. By simultaneously measuring gene expression and the accessibility of genomic regulatory regions at the single-cell level, they captured molecular branching points that determine drug sensitivity and resistance.

Analysis revealed that tumors exhibiting high sensitivity to AI displayed distinct characteristics even prior to treatment. They showed highly active ER-linked enhancers (regions that promote gene expression) alongside robust estrogen signaling activity. This was closely accompanied by an anti-cancer immune response from activated T cells within the tumor microenvironment. This indicates that the cancer cells maintained a strong dependence on estrogen and were vulnerable to immune system attacks.

Conversely, tumors that acquired drug resistance activated the androgen signaling pathway through epigenetic reconfiguration of hormone-sensing enhancers. With estrogen blocked, they altered the nature of gene regulatory regions, effectively repurposing male hormone signals as an alternative engine for tumor proliferation. In this process, remodeling of the tumor microenvironment to evade immune cell attacks was also observed. It is explained that drug pressure was circumvented by switching the gene expression regulation switches, even though the gene's base sequence itself remained unchanged.

Significance and Prospects

This study holds significant academic value by demonstrating that hormone therapy resistance is not merely a genetic defect but a complex response involving epigenetic alterations and immune evasion. It provides specific targets necessary for designing patient-specific treatment strategies.

The potential for its use as a biomarker to predict treatment response has been unveiled. By examining patients' T-cell activity and ER-linked enhancer status at the early stages of treatment, it is possible to pre-select those who will respond well to AI monotherapy. Development of combination therapies targeting the androgen receptor signaling pathway, identified as a resistance mechanism, and hormone-sensing enhancers is also expected to gain momentum.

There are still challenges to be resolved before applying this to actual clinical settings. Longitudinal single-cell analysis technology is costly and involves complex data processing, making the barrier to entry high for routine testing in general hospitals. Additional clinical trials are needed to confirm whether this discovery is reproducible across large patient cohorts of diverse races and disease stages.